3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
77.7
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/12/2022
Compliance Officer - 31/12/2021
Investor Relations Contact - 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/25 Issuer sale

Director

85,011 0.1134%
01/07/25 Issuer sale

Chief Financial Officer

738,955 0.9861%
01/07/25 Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--% - - 3.54B
-0.46%+10.31%+63.52%+143.15% 1,263B
-0.97%+1.60%+43.25%+80.09% 658B
-2.05%+0.73%+32.47%+101.62% 521B
-1.54%+0.18%+53.42%+66.79% 391B
-0.78%+5.51%+72.55%+44.25% 369B
-1.69%+3.17%+32.49%+55.35% 307B
-0.72%+7.83%+11.15%+33.76% 290B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 212B
Average -0.79%+5.08%+45.22%+78.81% 473.55B
Weighted average by Cap. -0.73%+5.66%+49.15%+93.29%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock